<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697485</url>
  </required_header>
  <id_info>
    <org_study_id>STU00213243</org_study_id>
    <nct_id>NCT04697485</nct_id>
  </id_info>
  <brief_title>Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus</brief_title>
  <official_title>Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, non-randomzied pilot study investigating a combination of targeted&#xD;
      therapies as possible treatment for heart failure with preserved ejection fraction (HFpEF).&#xD;
&#xD;
      The study interviention is a Low-Dose, Triple Polydiuretic Therapy (LDTPT, or polydiuretic)&#xD;
      including loop diuretic (bumetanide), mineralocorticoid receptor antagonist (eplerenone), and&#xD;
      Sodium-glucose co-transporter 2 inhibitors (SGLT2i) therapy (dapaglifozin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with HFpEF and diabetes mellitus will receive polydiuretic therapy consisting of&#xD;
      bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg on top of background therapy. These&#xD;
      medicines are currently FDA approved and recommended by clinical practice guidelines for the&#xD;
      treatment of HFpEF (bumetanide, eplerenone) and diabetes mellitus (dapaglifozin).&#xD;
&#xD;
      This study is designed to evaluate if combination pharmacotherapies with synergistic or&#xD;
      additive diuretic properties can improve adherence, treatment efficacy, and effectiveness&#xD;
      with fewer side effects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This will be a proof-of-concept, non-randomized, pilot study of patients with HFpEF and diabetes mellitus to receiving polydiuretic therapy (bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg) on top of background therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in NT-proBNP</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in NT-proBNP after 4 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic and Diastolic Blood pressure</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in blood pressure after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in weight after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overall compliance with polydiuretic as assessed by pill count</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HF - Heart Failure</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Low-Dose, Triple Polydiuretic Therapy (LDTPT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polydiuretic therapy will consist of bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg once daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg</intervention_name>
    <description>Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:&#xD;
Loop diuretic (bumetanide 0.5 mg)&#xD;
Mineralocorticoid receptor antagonist (eplerenone 25 mg)&#xD;
Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg</description>
    <arm_group_label>Low-Dose, Triple Polydiuretic Therapy (LDTPT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (≥18 years old)&#xD;
&#xD;
          2. English speaker&#xD;
&#xD;
          3. Established diagnosis of NYHA Class II or III heart failure with preserved ejection&#xD;
             fraction, which has been present for at least 2 months&#xD;
&#xD;
             a. NB: Patients in which additional pharmacological or device therapy is contemplated,&#xD;
             or should be considered, must not be enrolled until therapy has been optimized and is&#xD;
             stable for ≥1 month.&#xD;
&#xD;
          4. NT-proBNP &gt;600 pg/ml (or if hospitalized for heart failure within the previous 12&#xD;
             months, NT-proBNP ≥400 pg/ml) at enrolment (Visit 1)&#xD;
&#xD;
             a. If concomitant atrial fibrillation at Visit 1, NT-proBNP must be ≥900 pg/ml&#xD;
             (irrespective of history of heart failure hospitalization)&#xD;
&#xD;
          5. Type 2 diabetes mellitus, regardless of background insulin use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known contraindication to bumetanide, eplerenone, or dapagliflozin.&#xD;
&#xD;
          2. Symptomatic hypotension or systolic BP &lt;95 mmHg at 2 out of 3 measurements at visit 1.&#xD;
&#xD;
          3. Current acute decompensated HF or hospitalization due to decompensated HF &lt;4 weeks&#xD;
             prior to enrolment.&#xD;
&#xD;
          4. Myocardial infarction, unstable angina, stroke or transient ischemic attack (TIA)&#xD;
             within 12 weeks prior to enrollment.&#xD;
&#xD;
          5. HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis,&#xD;
             hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease.&#xD;
&#xD;
          6. Type 1 diabetes mellitus&#xD;
&#xD;
          7. Symptomatic bradycardia or second or third-degree heart block without a pacemaker.&#xD;
&#xD;
          8. Evidence of secondary cause of hypertension e.g., renal artery stenosis; significant&#xD;
             renal impairment (eGFR &lt;50 ml/min/1.73 m2), raised serum potassium (above lab normal&#xD;
             limit of 5.5 mEq/L).&#xD;
&#xD;
          9. Women who are pregnant, breast feeding or of childbearing potential and are not using&#xD;
             and do not plan to continue using medically acceptable form of contraception&#xD;
             throughout the study (pharmacological or barrier methods).&#xD;
&#xD;
         10. Concomitant illness, physical impairment or mental condition which in the opinion of&#xD;
             the study team / primary care physician could interfere with the conduct of the study&#xD;
             including outcome assessment.&#xD;
&#xD;
         11. Participation in a concurrent interventional medical investigation or pharmacologic&#xD;
             clinical trial. Patients in observational, natural history or epidemiological studies&#xD;
             not involving an intervention are eligible.&#xD;
&#xD;
         12. Participant's responsible primary care or other responsible physician believes it is&#xD;
             not appropriate for participant to participate in the study.&#xD;
&#xD;
         13. Inability or unwillingness to provide written informed consent.&#xD;
&#xD;
         14. Involvement in the planning and/or conduct of the study.&#xD;
&#xD;
         15. Receiving current treatment with sulfonylureas.&#xD;
&#xD;
         16. Unable to complete study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sadiya Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sadiya Khan, MD</last_name>
    <phone>312-503-2515</phone>
    <email>s-khan-1@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Huffman, MD</last_name>
    <phone>312-503-5513</phone>
    <email>m-huffman@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Sanchez</last_name>
      <phone>312-695-5097</phone>
      <email>cynthia.sanchez@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Anna Huskin</last_name>
      <phone>3126954067</phone>
      <email>anna.huskin@nm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Huffman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Sadiya Khan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

